0000899243-21-024250.txt : 20210616
0000899243-21-024250.hdr.sgml : 20210616
20210616191851
ACCESSION NUMBER: 0000899243-21-024250
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210616
FILED AS OF DATE: 20210616
DATE AS OF CHANGE: 20210616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
CENTRAL INDEX KEY: 0001787092
STATE OF INCORPORATION: E9
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40489
FILM NUMBER: 211022854
BUSINESS ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (617) 951-5372
MAIL ADDRESS:
STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC
STREET 2: 280 CONGRESS STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verve Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824800132
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: (978) 501-3026
MAIL ADDRESS:
STREET 1: 500 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2021-06-16
0
0001840574
Verve Therapeutics, Inc.
VERV
0001787092
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
C/O WELLINGTON MANAGEMENT COMPANY LLP
280 CONGRESS STREET
BOSTON
MA
02210
0
0
1
0
Series A-2 Preferred Stock
Common Stock
1343081
D
Series B Preferred Stock
Common Stock
1152490
D
The Series A-2 Preferred Stock is convertible into common stock on a 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
The Series B Preferred Stock is convertible into common stock on a 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
/s/ Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person
2021-06-16